Hims & Hers shares drop on doubts over weight-loss business forecast
Shares of Hims & Hers Health tumbled 18% premarket on Tuesday as Wall Street analysts questioned the telehealth provider's ...
Novo Nordisk Stock Rallies on Weight-Loss Retreat by Hims & Hers
Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to ...
Investor's Business Daily on MSN12m
Dow Jones Futures: Trump Tariffs 'Going Forward;' Hims Stock Crashes On Earnings
The Dow Jones Industrial Average and other major stock futures tentatively ventured into positive ground Tuesday as Wall ...
Hims & Hers flags possible halt to compounded weight-loss drug sales; shares slump
Investing.com - Hims&Hers (NYSE:HIMS) said on Monday that it may stop selling legal copies of a popular weight-loss drug made by Denmark's Novo Nordisk (NYSE:NVO), sending shares in the U.S.
devdiscourse42m
Healthcare Dynamics: Challenges and Innovations Amid Global Shifts
A series of important developments in the healthcare sector includes Medtronic adapting to tariff threats, Hims & Hers facing ...
StockStory.org on MSN41m
Tandem Diabetes (TNDM) Q4 Earnings: What To Expect
Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) will be reporting earnings tomorrow after the bell. Here’s ...
pharmaphorum55m
Lilly launches discounted Zepbound vials in US
Lilly recently revised its revenue forecast for 2024 after seeing weaker-than-expected growth for Zepbound and diabetes brand ...